<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 21 - FOOD AND DRUGS</title></head><body>
<span style="font-weight:bold;font-size:12pt;">21 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 2009 Edition</span><br/>
<span style="font-size:10pt">Title 21 - FOOD AND DRUGS</span><br/>
<span style="font-size:10pt">CHAPTER 9 - FEDERAL FOOD, DRUG, AND COSMETIC ACT</span><br/>
<span style="font-size:10pt">Front Matter</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- field-start:notes -->
<!-- field-start:miscellaneous-note -->
<h4 class="note-head">Part A&mdash;Drugs and Devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">351.</div><div class="two-column-analysis-style-content-right">Adulterated drugs and devices.</div></div>
<div><div class="two-column-analysis-style-content-left">352.</div><div class="two-column-analysis-style-content-right">Misbranded drugs and devices.</div></div>
<div><div class="two-column-analysis-style-content-left">353.</div><div class="two-column-analysis-style-content-right">Exemptions and consideration for certain drugs, devices, and biological products.</div></div>
<div><div class="two-column-analysis-style-content-left">353a.</div><div class="two-column-analysis-style-content-right">Pharmacy compounding.</div></div>
<div><div class="two-column-analysis-style-content-left">353b.</div><div class="two-column-analysis-style-content-right">Prereview of television advertisements.</div></div>
<div><div class="two-column-analysis-style-content-left">354.</div><div class="two-column-analysis-style-content-right">Veterinary feed directive drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">355.</div><div class="two-column-analysis-style-content-right">New drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">355&ndash;1.</div><div class="two-column-analysis-style-content-right">Risk evaluation and mitigation strategies.</div></div>
<div><div class="two-column-analysis-style-content-left">355a.</div><div class="two-column-analysis-style-content-right">Pediatric studies of drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">355b.</div><div class="two-column-analysis-style-content-right">Adverse-event reporting.</div></div>
<div><div class="two-column-analysis-style-content-left">355c.</div><div class="two-column-analysis-style-content-right">Research into pediatric uses for drugs and biological products.</div></div>
<div><div class="two-column-analysis-style-content-left">355d.</div><div class="two-column-analysis-style-content-right">Internal committee for review of pediatric plans, assessments, deferrals, and waivers.</div></div>
<div><div class="two-column-analysis-style-content-left">355e.</div><div class="two-column-analysis-style-content-right">Pharmaceutical security.</div></div>
<div><div class="two-column-analysis-style-content-left">356.</div><div class="two-column-analysis-style-content-right">Fast track products.</div></div>
<div><div class="two-column-analysis-style-content-left">356&ndash;1.</div><div class="two-column-analysis-style-content-right">Accelerated approval of priority countermeasures.</div></div>
<div><div class="two-column-analysis-style-content-left">356a.</div><div class="two-column-analysis-style-content-right">Manufacturing changes.</div></div>
<div><div class="two-column-analysis-style-content-left">356b.</div><div class="two-column-analysis-style-content-right">Reports of postmarketing studies.</div></div>
<div><div class="two-column-analysis-style-content-left">356c.</div><div class="two-column-analysis-style-content-right">Discontinuance of life saving product.</div></div>
<div><div class="two-column-analysis-style-content-left">357.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">358.</div><div class="two-column-analysis-style-content-right">Authority to designate official names.</div></div>
<div><div class="two-column-analysis-style-content-left">359.</div><div class="two-column-analysis-style-content-right">Nonapplicability of subchapter to cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">360.</div><div class="two-column-analysis-style-content-right">Registration of producers of drugs or devices.</div></div>
<div><div class="two-column-analysis-style-content-left">360a.</div><div class="two-column-analysis-style-content-right">Clinical trial guidance for antibiotic drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">360b.</div><div class="two-column-analysis-style-content-right">New animal drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">360c.</div><div class="two-column-analysis-style-content-right">Classification of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-left">360d.</div><div class="two-column-analysis-style-content-right">Performance standards.</div></div>
<div><div class="two-column-analysis-style-content-left">360e.</div><div class="two-column-analysis-style-content-right">Premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-left">360e&ndash;1.</div><div class="two-column-analysis-style-content-right">Pediatric uses of devices.</div></div>
<div><div class="two-column-analysis-style-content-left">360f.</div><div class="two-column-analysis-style-content-right">Banned devices.</div></div>
<div><div class="two-column-analysis-style-content-left">360g.</div><div class="two-column-analysis-style-content-right">Judicial review.</div></div>
<div><div class="two-column-analysis-style-content-left">360h.</div><div class="two-column-analysis-style-content-right">Notification and other remedies.</div></div>
<div><div class="two-column-analysis-style-content-left">360i.</div><div class="two-column-analysis-style-content-right">Records and reports on devices.</div></div>
<div><div class="two-column-analysis-style-content-left">360j.</div><div class="two-column-analysis-style-content-right">General provisions respecting control of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-left">360k.</div><div class="two-column-analysis-style-content-right">State and local requirements respecting devices.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>l.</em></div><div class="two-column-analysis-style-content-right">Postmarket surveillance.</div></div>
<div><div class="two-column-analysis-style-content-left">360m.</div><div class="two-column-analysis-style-content-right">Accredited persons.</div></div>
<div><div class="two-column-analysis-style-content-left">360n.</div><div class="two-column-analysis-style-content-right">Priority review to encourage treatments for tropical diseases.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part B&mdash;Drugs for Rare Diseases or Conditions</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360aa.</div><div class="two-column-analysis-style-content-right">Recommendations for investigations of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-left">360bb.</div><div class="two-column-analysis-style-content-right">Designation of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-left">360cc.</div><div class="two-column-analysis-style-content-right">Protection for drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-left">360dd.</div><div class="two-column-analysis-style-content-right">Open protocols for investigations of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-left">360ee.</div><div class="two-column-analysis-style-content-right">Grants and contracts for development of drugs for rare diseases and conditions.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part C&mdash;Electronic Product Radiation Control</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360hh.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">360ii.</div><div class="two-column-analysis-style-content-right">Program of control.</div></div>
<div><div class="two-column-analysis-style-content-left">360jj.</div><div class="two-column-analysis-style-content-right">Studies by Secretary.</div></div>
<div><div class="two-column-analysis-style-content-left">360kk.</div><div class="two-column-analysis-style-content-right">Performance standards for electronic products.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>ll.</em></div><div class="two-column-analysis-style-content-right">Notification of defects in and repair or replacement of electronic products.</div></div>
<div><div class="two-column-analysis-style-content-left">360mm.</div><div class="two-column-analysis-style-content-right">Imports.</div></div>
<div><div class="two-column-analysis-style-content-left">360nn.</div><div class="two-column-analysis-style-content-right">Inspection, records, and reports.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>oo.</em></div><div class="two-column-analysis-style-content-right">Prohibited acts.</div></div>
<div><div class="two-column-analysis-style-content-left">360pp.</div><div class="two-column-analysis-style-content-right">Enforcement.</div></div>
<div><div class="two-column-analysis-style-content-left">360qq.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">360rr.</div><div class="two-column-analysis-style-content-right">Federal-State cooperation.</div></div>
<div><div class="two-column-analysis-style-content-left">360ss.</div><div class="two-column-analysis-style-content-right">State standards.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part D&mdash;Dissemination of Treatment Information</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left" id="wide">360aaa to 360aaa&ndash;6. Omitted</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part E&mdash;General Provisions Relating to Drugs and Devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360bbb.</div><div class="two-column-analysis-style-content-right">Expanded access to unapproved therapies and diagnostics.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;1.</div><div class="two-column-analysis-style-content-right">Dispute resolution.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;2.</div><div class="two-column-analysis-style-content-right">Classification of products.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;3.</div><div class="two-column-analysis-style-content-right">Authorization for medical products for use in emergencies.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;4.</div><div class="two-column-analysis-style-content-right">Technical assistance.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;5.</div><div class="two-column-analysis-style-content-right">Critical Path Public-Private Partnerships.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;6.</div><div class="two-column-analysis-style-content-right">Risk communication.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part F&mdash;New Animal Drugs for Minor Use and Minor Species</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360ccc.</div><div class="two-column-analysis-style-content-right">Conditional approval of new animal drugs for minor use and minor species.</div></div>
<div><div class="two-column-analysis-style-content-left">360ccc&ndash;1.</div><div class="two-column-analysis-style-content-right">Index of legally marketed unapproved new animal drugs for minor species.</div></div>
<div><div class="two-column-analysis-style-content-left">360ccc&ndash;2.</div><div class="two-column-analysis-style-content-right">Designated new animal drugs for minor use or minor species.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VI&mdash;COSMETICS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">361.</div><div class="two-column-analysis-style-content-right">Adulterated cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">362.</div><div class="two-column-analysis-style-content-right">Misbranded cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">363.</div><div class="two-column-analysis-style-content-right">Regulations making exemptions.</div></div>
<div><div class="two-column-analysis-style-content-left">364.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VII&mdash;GENERAL AUTHORITY</h4>
<h4 class="note-head">Part A&mdash;General Administrative Provisions</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">371.</div><div class="two-column-analysis-style-content-right">Regulations and hearings.</div></div>
<div><div class="two-column-analysis-style-content-left">372.</div><div class="two-column-analysis-style-content-right">Examinations and investigations.</div></div>
<div><div class="two-column-analysis-style-content-left">372a.</div><div class="two-column-analysis-style-content-right">Transferred.</div></div>
<div><div class="two-column-analysis-style-content-left">373.</div><div class="two-column-analysis-style-content-right">Records.</div></div>
<div><div class="two-column-analysis-style-content-left">374.</div><div class="two-column-analysis-style-content-right">Inspection.</div></div>
<div><div class="two-column-analysis-style-content-left">374a.</div><div class="two-column-analysis-style-content-right">Inspections relating to food allergens.</div></div>
<div><div class="two-column-analysis-style-content-left">375.</div><div class="two-column-analysis-style-content-right">Publicity.</div></div>
<div><div class="two-column-analysis-style-content-left">376.</div><div class="two-column-analysis-style-content-right">Examination of sea food on request of packer; marking food with results; fees; penalties.</div></div>
<div><div class="two-column-analysis-style-content-left">377.</div><div class="two-column-analysis-style-content-right">Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests.</div></div>
<div><div class="two-column-analysis-style-content-left">378.</div><div class="two-column-analysis-style-content-right">Advertising of foods.</div></div>
<div><div class="two-column-analysis-style-content-left">379.</div><div class="two-column-analysis-style-content-right">Confidential information.</div></div>
<div><div class="two-column-analysis-style-content-left">379a.</div><div class="two-column-analysis-style-content-right">Presumption of existence of jurisdiction.</div></div>
<div><div class="two-column-analysis-style-content-left">379b.</div><div class="two-column-analysis-style-content-right">Consolidated administrative and laboratory facility.</div></div>
<div><div class="two-column-analysis-style-content-left">379c.</div><div class="two-column-analysis-style-content-right">Transferred.</div></div>
<div><div class="two-column-analysis-style-content-left">379d.</div><div class="two-column-analysis-style-content-right">Automation of Food and Drug Administration.</div></div>
<div><div class="two-column-analysis-style-content-left">379d&ndash;1.</div><div class="two-column-analysis-style-content-right">Conflicts of interest.</div></div>
<div><div class="two-column-analysis-style-content-left">379d&ndash;2.</div><div class="two-column-analysis-style-content-right">Policy on the review and clearance of scientific articles published by FDA employees.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part B&mdash;Colors</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379e.</div><div class="two-column-analysis-style-content-right">Listing and certification of color additives for foods, drugs, devices, and cosmetics.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part C&mdash;Fees</h4>
I74subpart 1&mdash;freedom of information fees<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379f.</div><div class="two-column-analysis-style-content-right">Recovery and retention of fees for freedom of information requests.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 2&mdash;fees relating to drugs</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379g.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">379h.</div><div class="two-column-analysis-style-content-right">Authority to assess and use drug fees.</div></div>
<div><div class="two-column-analysis-style-content-left">379h&ndash;1.</div><div class="two-column-analysis-style-content-right">Fees relating to advisory review of prescription-drug television advertising.</div></div>
<div><div class="two-column-analysis-style-content-left">379h&ndash;2.</div><div class="two-column-analysis-style-content-right">Reauthorization; reporting requirements.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 3&mdash;fees relating to devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379i.</div><div class="two-column-analysis-style-content-right">Definitions.<!-- PDFPage:27 --></div></div>
<div><div class="two-column-analysis-style-content-left">379j.</div><div class="two-column-analysis-style-content-right">Authority to assess and use device fees.</div></div>
<div><div class="two-column-analysis-style-content-left">379j&ndash;1.</div><div class="two-column-analysis-style-content-right">Reauthorization; reporting requirements.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 4&mdash;fees relating to animal drugs</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379j&ndash;11.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">379j&ndash;12.</div><div class="two-column-analysis-style-content-right">Authority to assess and use animal drug fees.</div></div>
<div><div class="two-column-analysis-style-content-left">379j&ndash;13.</div><div class="two-column-analysis-style-content-right">Reauthorization; reporting requirements.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 5&mdash;fees relating to generic new animal drugs</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379j&ndash;21.</div><div class="two-column-analysis-style-content-right">Authority to assess and use generic new animal drug fees.</div></div>
<div><div class="two-column-analysis-style-content-left">379j&ndash;22.</div><div class="two-column-analysis-style-content-right">Reauthorization; reporting requirements.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part D&mdash;Information and Education</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379k.</div><div class="two-column-analysis-style-content-right">Information system.</div></div>
<div><div class="two-column-analysis-style-content-left">379<em>l</em>.</div><div class="two-column-analysis-style-content-right">Education.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part E&mdash;Environmental Impact Review</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379<em>o</em>.</div><div class="two-column-analysis-style-content-right">Environmental impact.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part F&mdash;National Uniformity for Nonprescription Drugs and Preemption for Labeling or Packaging of Cosmetics</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379r.</div><div class="two-column-analysis-style-content-right">National uniformity for nonprescription drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">379s.</div><div class="two-column-analysis-style-content-right">Preemption for labeling or packaging of cosmetics.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part G&mdash;Safety Reports</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379v.</div><div class="two-column-analysis-style-content-right">Safety report disclaimers.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part H&mdash;Serious Adverse Event Reports</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379aa.</div><div class="two-column-analysis-style-content-right">Serious adverse event reporting for nonprescription drugs.</div></div>
<div><div class="two-column-analysis-style-content-left">379aa&ndash;1.</div><div class="two-column-analysis-style-content-right">Serious adverse event reporting for dietary supplements.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part I&mdash;Reagan-Udall Foundation for the Food and Drug Administration</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379dd.</div><div class="two-column-analysis-style-content-right">Establishment and functions of the Foundation.</div></div>
<div><div class="two-column-analysis-style-content-left">379dd&ndash;1.</div><div class="two-column-analysis-style-content-right">Location of Foundation.</div></div>
<div><div class="two-column-analysis-style-content-left">379dd&ndash;2.</div><div class="two-column-analysis-style-content-right">Activities of the Food and Drug Administration.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VIII&mdash;IMPORTS AND EXPORTS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">381.</div><div class="two-column-analysis-style-content-right">Imports and exports.</div></div>
<div><div class="two-column-analysis-style-content-left">382.</div><div class="two-column-analysis-style-content-right">Exports of certain unapproved products.</div></div>
<div><div class="two-column-analysis-style-content-left">383.</div><div class="two-column-analysis-style-content-right">Office of International Relations.</div></div>
<div><div class="two-column-analysis-style-content-left">384.</div><div class="two-column-analysis-style-content-right">Importation of prescription drugs.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER IX&mdash;TOBACCO PRODUCTS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">387.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">387a.</div><div class="two-column-analysis-style-content-right">FDA authority over tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387a&ndash;1.</div><div class="two-column-analysis-style-content-right">Final rule.</div></div>
<div><div class="two-column-analysis-style-content-left">387b.</div><div class="two-column-analysis-style-content-right">Adulterated tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387c.</div><div class="two-column-analysis-style-content-right">Misbranded tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387d.</div><div class="two-column-analysis-style-content-right">Submission of health information to the Secretary.</div></div>
<div><div class="two-column-analysis-style-content-left">387e.</div><div class="two-column-analysis-style-content-right">Annual registration.</div></div>
<div><div class="two-column-analysis-style-content-left">387f.</div><div class="two-column-analysis-style-content-right">General provisions respecting control of tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387f&ndash;1.</div><div class="two-column-analysis-style-content-right">Enforcement action plan for advertising and promotion restrictions.</div></div>
<div><div class="two-column-analysis-style-content-left">387g.</div><div class="two-column-analysis-style-content-right">Tobacco product standards.</div></div>
<div><div class="two-column-analysis-style-content-left">387h.</div><div class="two-column-analysis-style-content-right">Notification and other remedies.</div></div>
<div><div class="two-column-analysis-style-content-left">387i.</div><div class="two-column-analysis-style-content-right">Records and reports on tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387j.</div><div class="two-column-analysis-style-content-right">Application for review of certain tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387k.</div><div class="two-column-analysis-style-content-right">Modified risk tobacco products.</div></div>
<div><div class="two-column-analysis-style-content-left">387<em>l</em>.</div><div class="two-column-analysis-style-content-right">Judicial review.</div></div>
<div><div class="two-column-analysis-style-content-left">387m.</div><div class="two-column-analysis-style-content-right">Equal treatment of retail outlets.</div></div>
<div><div class="two-column-analysis-style-content-left">387n.</div><div class="two-column-analysis-style-content-right">Jurisdiction of and coordination with the Federal Trade Commission.</div></div>
<div><div class="two-column-analysis-style-content-left">387<em>o</em>.</div><div class="two-column-analysis-style-content-right">Regulation requirement.</div></div>
<div><div class="two-column-analysis-style-content-left">387p.</div><div class="two-column-analysis-style-content-right">Preservation of State and local authority.</div></div>
<div><div class="two-column-analysis-style-content-left">387q.</div><div class="two-column-analysis-style-content-right">Tobacco Products Scientific Advisory Committee.</div></div>
<div><div class="two-column-analysis-style-content-left">387r.</div><div class="two-column-analysis-style-content-right">Drug products used to treat tobacco dependence.</div></div>
<div><div class="two-column-analysis-style-content-left">387s.</div><div class="two-column-analysis-style-content-right">User fees.</div></div>
<div><div class="two-column-analysis-style-content-left">387t.</div><div class="two-column-analysis-style-content-right">Labeling, recordkeeping, records inspection.</div></div>
<div><div class="two-column-analysis-style-content-left">387u.</div><div class="two-column-analysis-style-content-right">Studies of progress and effectiveness.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER X&mdash;MISCELLANEOUS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">391.</div><div class="two-column-analysis-style-content-right">Separability clause.</div></div>
<div><div class="two-column-analysis-style-content-left">392.</div><div class="two-column-analysis-style-content-right">Exemption of meats and meat food products.</div></div>
<div><div class="two-column-analysis-style-content-left">393.</div><div class="two-column-analysis-style-content-right">Food and Drug Administration.</div></div>
<div><div class="two-column-analysis-style-content-left">393a.</div><div class="two-column-analysis-style-content-right">Office of Pediatric Therapeutics.</div></div>
<div><div class="two-column-analysis-style-content-left">394.</div><div class="two-column-analysis-style-content-right">Scientific review groups.</div></div>
<div><div class="two-column-analysis-style-content-left">395.</div><div class="two-column-analysis-style-content-right">Loan repayment program.</div></div>
<div><div class="two-column-analysis-style-content-left">396.</div><div class="two-column-analysis-style-content-right">Practice of medicine.</div></div>
<div><div class="two-column-analysis-style-content-left">397.</div><div class="two-column-analysis-style-content-right">Contracts for expert review.</div></div>
<div><div class="two-column-analysis-style-content-left">398.</div><div class="two-column-analysis-style-content-right">Notices to States regarding imported food.</div></div>
<div><div class="two-column-analysis-style-content-left">399.</div><div class="two-column-analysis-style-content-right">Grants to States for inspections.</div></div>
<div><div class="two-column-analysis-style-content-left">399a.</div><div class="two-column-analysis-style-content-right">Office of the Chief Scientist.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- field-end:miscellaneous-note -->
<!-- field-end:notes -->


</body></html>